Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection to Treat Moderate to Severe Glabellar Lines

Launched by JHM BIOPHARMA (TONGHUA) CO. , LTD. · Apr 14, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called Eveotox, which is a type of botulinum toxin, for reducing moderate to severe lines between the eyebrows, known as glabellar lines. The trial is divided into two parts: the first part involves giving a single injection of Eveotox to some participants and comparing the results to those who receive either a placebo (a substance with no active effect) or another treatment. The second part will look at how effective and safe Eveotox is when given in repeated injections over time.

To be eligible for this trial, participants must be between 18 and 65 years old and have noticeable glabellar lines when frowning. Those with certain health conditions, such as allergies to similar treatments or specific skin problems, will not be able to participate. Individuals who join the study can expect to attend scheduled visits, follow trial procedures, and help researchers understand how well Eveotox works and its safety for treating these lines.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male or female subjects who are between 18 to 65 years of age
• • Moderate or severe glabellar lines during maximum frown based on the Investigator Global Assessment Frown Wrinkle Severity scale
• • Moderate or severe glabellar lines during maximum frown based on the Patient Frown Wrinkle Severity scale
• • Willing and able to follow all trial procedures, attend all scheduled visits, and successfully complete the trial
• Exclusion Criteria:
• • Subjects who have a history of oversensitivity to the Botulinum Toxin A type or other components of the study drug
• • Subjects who have implanted any permanent materials in the glabellar area or received semi-permanent fillers within the first 2 years of screening
• • Subjects with active skin infections at the injection site or systemic skin disease, which the investigator judges can affect the evaluation of efficacy or safety
• • Subjects who have a history of injecting drugs similar to the study drug within 6 months prior to selection or are foreseen to use during the study period